



Contents lists available at [ScienceDirect](#)

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Corrigendum

Corrigendum to “Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: Alleviating hERG interactions through structure based design” [Bioorg. Med. Chem. Lett. 19 (2009) 3339]

Snahel D. Patel[†], Wendy M. Habeski, Alan C. Cheng[‡], Elisa de la Cruz, Christine Loh[§], Natasha M. Kablaoui^{*}

Pfizer Global Research and Development, Cambridge Laboratories, Cambridge, MA 02139, USA

The authors regret that the following acknowledgement was omitted:

PC-1 recombinant enzyme was a generous gift of Dr. James Goding, Monash University, Victoria, Australia.

DOI of original article: [10.1016/j.bmcl.2009.04.006](https://doi.org/10.1016/j.bmcl.2009.04.006)

^{*} Corresponding author. Tel.: +1 617 551 3473; fax: +1 860 686 8090.

E-mail address: Natasha.m.kablaoui@pfizer.com (N.M. Kablaoui).

[†] Present address: Genentech Inc., South San Francisco, CA 94080, USA.

[‡] Present address: Amgen Inc., Cambridge, MA 02139, USA.

[§] Present address: Sirtris Pharmaceuticals, Cambridge, MA 02139, USA.